What is Cardeas Pharma?
Cardeas Pharma operates as a specialized biopharmaceutical entity focused on the development of inhaled antibiotics designed to combat highly resistant organisms in hospital settings. The company distinguishes itself by integrating novel antibiotic formulations with advanced delivery technologies, effectively targeting respiratory infections that remain resistant to conventional treatment modalities. By focusing on the critical-care market, Cardeas Pharma addresses a high-acuity medical need, positioning itself as a key player in the fight against antibiotic resistance. Its market position is defined by a commitment to bridging the gap between laboratory-stage drug discovery and clinical-grade commercial application.
How much funding has Cardeas Pharma raised?
Cardeas Pharma has raised a total of $41.5M across 2 funding rounds:
Series A
$7.5M
Series B
$34M
Series A (2012): $7.5M, investors not publicly disclosed
Series B (2013): $34M led by Devon Park Bioventures, Avalon Ventures, Washington Research Foundation, Novo A/S, Delphi Ventures, and H.I.G. BioVentures, LLC
Key Investors in Cardeas Pharma
Avalon Ventures
A venture capital firm with over three decades of experience specializing in seed and early-stage investments within the life sciences and information technology sectors.
Novo A/S
A Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term investments in life science companies.
H.I.G. BioVentures, LLC
A global alternative investment firm providing debt and equity capital to middle-market companies with a dedicated focus on healthcare and life sciences innovation.
What's next for Cardeas Pharma?
With the successful closure of its recent funding, Cardeas Pharma is expected to prioritize the advancement of its lead candidates through late-stage clinical trials. The strategic deployment of these funds will likely focus on scaling manufacturing capabilities and expanding regulatory engagement to facilitate the commercial rollout of its inhaled antibiotic solutions. As the company matures, the focus will shift toward establishing partnerships with major healthcare providers and hospital networks to integrate its delivery technology into standard critical-care protocols. This trajectory suggests a long-term objective of becoming a dominant force in the respiratory therapeutics market, potentially attracting further interest from institutional investors or strategic acquirers within the life sciences sector.
See full Cardeas Pharma company page
